Erratum: Figitumumab (CP-751,871) for cancer therapy (Expert Opinion on Biological Therapy (2010) 10:4 (575-585) DOI: 10.1517/14712591003689980);Figitumumab (CP-751,871) for cancer therapy

Expert Opinion on Biological Therapy

Volumn 10, Issue 4, 2010, Pages 575-585

  Gualberto, Antonio ^a  

^a PFIZER INC   (United States)

Author keywords

Cancer; CP 751; Figitumumab; IGF IR; IGF1R

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CP 751871; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; EVEROLIMUS; EXEMESTANE; FIGITUMUMAB; FLUOROURACIL; GEMCITABINE; PACLITAXEL; PEGVISOMANT; PEMETREXED; PREDNISONE; RAPAMYCIN; SOMATOMEDIN BINDING PROTEIN; SUNITINIB; UNCLASSIFIED DRUG;

ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; ASTHENIA; BREAST CANCER; CLINICAL TRIAL; COLORECTAL CANCER; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG ACTIVITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SENSITIVITY; DRUG TOLERABILITY; EWING SARCOMA; FATIGUE; FEBRILE NEUTROPENIA; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERURICEMIA; LIVER FUNCTION TEST; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE WEAKNESS; NAUSEA; NEUTROPENIA; PROSTATE CANCER; REVIEW; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT RESPONSE; URIC ACID BLOOD LEVEL;

EID: 77949448133     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2014.902914     Document Type: Erratum

References (72)

1. LeRoith D, Toberts CT. The insulin-like growth factor system and cancer. Cancer Lett 2003;195:127-137
2. Yee D. Targeting insulin-like growth factor pathways. Br J Cancer 2006;94:465-468
3. Yuen JS, Macaulay VM. Targeting the Type 1 insulin-like growth factor receptor as a treatment for cancer. Expert Opin Ther Targets 2008;12:589-603
4. Himpe E, Kooijman R. Insulin-like growth factor-I receptor signal transduction and the janus kinase/signal transducer and activator of transcription (JAK-STAT) pathway. Biofactors 2009;35:76-81
5. Hernández-Sánchez C, Mansilla A, de Pablo F, et al. Evolution of the insulin receptor family and receptor isoform expression in vertebrates. Mol Biol Evol 2008;25:1043-1053
6. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004;4:505-518
7. Liu JP, Baker J, Perkins AS, et al. Mice carrying null mutations of the genes encoding insulin-like growth factor I (IGF-I) and Type 1 IGF receptor (Igf1r). Cell 1993;75:59-72
8. Abuzzahab MJ, Schneider A, Goddard A, et al. IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation. N Engl J Med 2003;349:2211-2222
9. Liu JP, Baker J, Perkins AS, et al. Mice carrying null mutations of the genes encoding insulin-like growth factor I (IGF-I) and Type 1 IGF receptor (Igf1r). Cell 1993;75:59-72
10. Laustsen PG, Russell SJ, Cui L, et al. Essential role of insulin and insulin-like growth factor 1 receptor signaling in cardiac development and function. Mol Cell Biol 2007;27:1649-1664
11. Russo VC, Gluckman PD, Feldman EL, Werther GA. The insulin-like growth factor system and its pleiotropic functions in brain. Endocr Rev 2005;26:916-943
12. Frystyk J, Ivarsen P, Skjaerbaek C, et al. Serum-free insulin-like growth factor I correlates with clearance in patients with chronic renal failure. Kidney Int 1999;56:2076-2084
13. Guler HP, Schmid C, Zapf J, Froesch ER. Effects of recombinant insulin-like growth factor 1 on insulin secretion and renal function in normal human subjects. Proc Natl Acad Sci USA 1989;86:2868-2872
14. Laughlin GA, Barrett-Connor E, Criqui MH, et al. The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. J Clin Endocrinol Metab 2004;89:114-120
15. Ezzat VA, Duncan ER, Wheatcroft SB, et al. The role of IGF-I and its binding proteins in the development of Type 2 diabetes and cardiovascular disease. Diabetes Obes Metab 2008;10:198-211
16. Janssen JA, Lamberts SW. The role of IGF-I in the development of cardiovascular disease in Type 2 diabetes mellitus: is prevention possible? Eur J Endocrinol 2002;146:467-477
17. Holzenberger M, Dupont J, Ducos B, et al. IGF-I receptor regulates lifespan and resistance to oxidative stress in mice. Nature 2003;421:182-187
18. Holzenberger M. The GH/IGF-I axis and longevity. Eur J Endocrinol 2004;151(Suppl 1):S23-7
19. Suh Y, Atzmon G, Cho MO, et al. Functionally significant insulin-like growth factor I receptor mutations in centenarians. Proc Natl Acad Sci USA 2008;105:3438-3442
20. Pinkston-Gosse J, Kenyon C. DAF-16/FOXO targets genes that regulate tumor growth in Caenorhabditis elegans. Nat Genet 2007;39:1403-1409
21. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995;16(1):3-34
22. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007;129:1261-1274
23. O'Connor R. Regulation of IGF-I receptor signaling in tumor cells. Horm Metab Res 2003;35:771-777
24. Wan X, Harkavy B, Shen N, et al. Rapamycin induces feedback activation of Akt signaling through an IGF-IRdependent mechanism. Oncogene 2007;26:1932-1940
25. Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 2007;6:1-12
26. Yuen JS, Macaulay VM. Targeting the Type 1 insulin-like growth factor receptor as a treatment for cancer. Expert Opin Ther Targets 2008;12:589-603
27. Samani AA, Yakar S, LeRoith D, et al. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007;28:20-47
28. Baserga R, Peruzzi F, Reiss K. The IGF-I receptor in cancer biology. Int J Cancer 2003;107:873-877
29. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008;8:915-928
30. Chitnis MM, Yuen JS, Protheroe AS, et al. The Type 1 insulin-like growth factor receptor pathway. Clin Cancer Res 2008;14:6364-6370
31. Hartog H, Wesseling J, Boezen HM, et al. The insulin-like growth factor 1 receptor in cancer: old focus, new future. Eur J Cancer 2007;43:1895-1904
32. Mendez MJ, Green LL, Corvalan JRF, et al. Functional transplant of megabase human immunoglobin loci recapitulates human antibody response in mice. Nat Genet 1997;15:146-156
33. Cohen BD, Baker DA, Soderstrom C, et al. Combination therapy enhances the inhibition of tumor growth with the fully human anti-Type 1 insulin-like growth factor receptor monoclonal antibody figitumumab. Clin. Cancer Res 2005;11:2063-2073
34. O'Mahony D, Bishop MR. Monoclonal antibody therapy. Front Biosci 2006;11:1620-1635
35. Iwasa T, Okamoto I, Suzuki M, et al. Inhibition of insulin-like growth factor 1 receptor by CP-751,871 radiosensitizes non-small cell lung cancer cells. Clin Cancer Res 2009;15:5117-5125
36. Kurmasheva RT, Dudkin L, Billups C, et al. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res 2009;69:7662-7671
37. Lacy MQ, Alsina M, Fonseca R, et al. Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor Type 1 Receptor monoclonal antibody figitumumab in patients with multiple myeloma. J Clin Oncol. 2008;26(19):3196-3203
38. Haluska P, Shaw HM, Batzel GN, et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody figitumumab in patients with refractory solid tumors. Clin Cancer Res 2007;13:5834-5840
39. Haluska P, Worden F, Olmos D, et al. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol 2010;65:765-773
40. Olmos D, Postel-Vinay S, Molife LR, et al. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a Phase 1 expansion cohort study. Lancet Oncol 2010;11:129-135
41. Karp DD, Pollak MN, Cohen RB, et al. Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor Type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin. J Thorac Oncol 2009;4:1397-1403
42. Attard G, Fong PC, Molife R, et al. Phase I trial involving the pharmacodynamic (PD) study of circulating tumour cells, of figitumumab (C), a monoclonal antibody against the insulin-like growth factor 1 receptor (IGF-IR), with docetaxel (D) in patients (p) with advanced cancer. J Clin Oncol 2006;24(Suppl):abstract 3023
43. Paz-Ares L, O'Byrne K, Corral J, et al. A phase I dose escalation study of gemcitabine and cisplatin with the anti-IGF-IR antibody figitumumab (CP-751,871) as first-line treatment of patients with advanced Non-Small Cell Lung Cancer (NSCLC). 13th World Conference on Lung Cancer, July 31st - August 4th, 2009, San Francisco, CA, P1228
44. Goto Y, Tanioka M, Shibata T, et al. Phase I dose-escalation study of CP-751,871 combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced non-small cell lung cancer (NSCLC). 13th World Conference on Lung Cancer, July 31st - August 4th, 2009, San Francisco, CA, P1181
45. de Bono JS, Attard G, Adjei A, et al. Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res 2007;13(12):3611-3616
46. Janne PA, Reckamp K, Koczywas M, et al. Efficacy and safety of PF-00299804 (PF299) in patients (pt) with advanced NSCLC after failure of at least one prior chemotherapy regimen and prior treatment with erlotinib (E): a two-arm, phase II trial. J Clin Oncol 2009;27:15s:8063
47. Karp DD, Paz-Ares LG, Novello S, et al. Phase II study of the anti-insulin-like growth factor Type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 2009;27:2516-2522
48. Karp DD, Novello S, Cardenal F, et al. Continued high activity of figitumumab (CP-751,871) combination therapy in squamous lung cancer. J Clin Oncol 2009;27:15s(Suppl):abstract 8072
49. Gualberto A, Dolled-Filhart MP, Hixon ML, et al. Molecular bases for sensitivity to figitumumab (CP-751,871) in NSCLC [abstract 8091]. J Clin Oncol 2009;27(suppl):15s
50. Reynolds JM, Lloyd DB, Bentivegna SC, et al. Insulin-like growth factor 1 receptor mutants are inhibited by figitumumab (CP-751-871) in vitro [abstract#B119]. AACR Molecular Targets and Cancer Therapeutics, Boston MA; 2009
51. M.L. Hixon, A. Gualberto, L. Demers, et al. Correlation of plasma levels of free insulin-like growth factor 1 and clinical benefit of the IGF-IR inhibitor figitumumab (CP- 751, 871) [abstract 3539]. J Clin Oncol 2009;27(Suppl):15s
52. Gualberto A, Hixon ML, Dolled-Fillhart MP, et al. The anti-IGF-IR antibody figitumumab (CP-751,871) is active in patients with lung adenocarcinoma undergoing epithelial-to-mesenchymal transition. Eur J Cancer 2009;7:88s
53. Lee PD, Conover CA, Powell DR. Regulation and function of insulin-like growth factor binding protein-1. Proc Soc Exp Biol Med 1993;204:4-29
54. Borai A, Livingstone C, Ferns GA. The biochemical assessment of insulin resistance. Ann Clin Biochem 2007;44:324-342
55. Wolpin BM, Meyerhardt JA, Chan AT, et al. Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. J Clin Oncol 2009;27:176-185
56. Pfizer Inc, data on file. www.pfizer.com
57. Gualberto A, Karp DD. Development of the monoclonal antibody figitumumab, targeting the insulin-like growth factor- 1 receptor, for the treatment of patients with non-small-cell lung cancer. Clin Lung Cancer 2009;10:273-280
58. Sandler AR, Gray RJ, Perry MC, et al. Paclitaxel-carboplatin alone or with Bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550
59. Manegold C, von Pawel J, Zatloukal P, et al. Randomised, double-blind multicentre phase III study of Bevacizumab in combination with Cisplatin and Gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704 [abstract LBA7514]. J Clin Oncol 2007;25:18S
60. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:200-202
61. Monk D, Sanches R, Arnaud P, et al. Imprinting of IGF2 P0 transcript and novel alternatively spliced INS-IGF2 isoforms show differences between mouse and human Hum Mol Genet 2006;15:1259-1269
62. Rother KI, Accili D. Role of insulin receptors and IGF receptors in growth and development. Pediatr Nephrol 2000;14:558-561
63. Eizirik DL, Pipeleers DG, Ling Z, et al. Major species differences between humans and rodents in the susceptibility to pancreatic beta-cell injury. Proc Natl Acad Sci USA 1994;91:9253-9256
64. Vassilopoulos S, Esk C, Hoshino S, et al. A role for the CHC22 clathrin heavy-chain isoform in human glucose metabolism. Science 2009;324:1192-1196
65. Cowey S, Hardy RW. The metabolic syndrome: a high-risk state for cancer? Am J Pathol 2006;169:1505-1522
66. Gualberto A, Pollak M. Clinical development of inhibitors of the insulin-like growth factor receptor in oncology. Curr Drug Targets 2009;10:923-936
67. Wahner Hendrickson AE, Haluska P, Schneider PA, et al. Expression of insulin receptor isoform A and insulinlike growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro. Cancer Res 2009;69:7635-7643
68. Atzori F, Tabernero J, Cervantes A, et al. A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qW) MK-0646, an insulin-like growth factor-1 receptor (IGF1R) monoclonal antibody (MAb) in patients (pts) with advanced solid tumors. J Clin Oncol 2008;26:157s
69. Hidalgo M, Tirado Gomez M, Lewis N, et al. A phase I study of MK-0646, a humanized monoclonal antibody against the insulin-like growth factor receptor Type 1 (IGF1R) in advanced solid tumor patients in a q2 wk schedule. J Clin Oncol 2008;26:158s
70. Cox ME, Gleave ME, Zakikhani M, et al. Insulin receptor expression by human prostate cancers. Prostate 2009;69:33-40
71. Law JH, Habibi G, Hu K, et al. Phosphorylated insulin-like growth factor-I/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 2008;68:10238-10246
72. Zhang H, Pelzer AM, Kiang DT, Yee D. Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin. Cancer Res 2007;67:391-397